当前位置: X-MOL 学术Annu. Rev. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus
Annual Review of Medicine ( IF 15.1 ) Pub Date : 2017-01-18 00:00:00 , DOI: 10.1146/annurev-med-051215-031152
Anthony R Fehr , Rudragouda Channappanavar , Stanley Perlman 1
Affiliation  

In 2012, a zoonotic coronavirus was identified as the causative agent of Middle East respiratory syndrome and was named MERS coronavirus (MERS-CoV). As of August 11, 2016, the virus has infected 1,791 patients, with a mortality rate of 35.6%. Although MERS-CoV generally causes subclinical or mild disease, infection can result in serious outcomes, including acute respiratory distress syndrome and multi-organ failure in patients with comorbidities. The virus is endemic in camels in the Arabian Peninsula and Africa and thus poses a consistent threat of frequent reintroduction into human populations. Disease prevalence will increase substantially if the virus mutates to increase human-to-human transmissibility. No therapeutics or vaccines are approved for MERS; thus, development of novel therapies is needed. Further, since many MERS cases are acquired in healthcare settings, public health measures and scrupulous attention to infection control are required to prevent additional MERS outbreaks.

中文翻译:



中东呼吸综合症:致病性人类冠状病毒的出现



2012年,一种人畜共患冠状病毒被确定为中东呼吸综合征的病原体,并被命名为中东呼吸综合征冠状病毒(MERS-CoV)。截至2016年8月11日,该病毒已感染1,791名患者,死亡率为35.6%。尽管中东呼吸综合征冠状病毒通常会引起亚临床或轻微疾病,但感染可能导致严重后果,包括急性呼吸窘迫综合征和合并症患者的多器官衰竭。该病毒在阿拉伯半岛和非洲的骆驼中流行,因此对频繁重新引入人类种群构成持续威胁。如果病毒发生突变以增加人与人之间的传播能力,疾病患病率将大幅增加。没有批准治疗 MERS 的疗法或疫苗;因此,需要开发新疗法。此外,由于许多中东呼吸综合征病例是在医疗机构中获得的,因此需要采取公共卫生措施并严格控制感染,以防止更多的中东呼吸综合征疫情爆发。

更新日期:2017-01-18
down
wechat
bug